首页> 外文期刊>Journal of drug targeting >Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes.
【24h】

Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes.

机译:肺部给药并入脂质体的环丙沙星后,粒径对给药至大鼠肺泡巨噬细胞的颗粒的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

In order to confirm the efficacy of ciprofloxacin (CPFX) incorporated into liposomes (CPFX-liposomes) for treatment of respiratory intracellular parasite infections, the influence of particle size on drug delivery to rat alveolar macrophages (AMs) following pulmonary administration of CPFX-liposomes was investigated. CPFX-liposomes were prepared with hydrogenated soybean phosphatidylcholine (HSPC), cholesterol (CH) and dicetylphosphate (DCP) in a lipid molar ratio of 7/2/1 by the hydration method and then adjusted to five different particle sizes (100, 200, 400, 1000 and 2000 nm). In the pharmacokinetic experiment, the delivery efficiency of CPFX to rat AMs following pulmonary administration of CPFX-liposomes increased with the increase in the particle size over the range 100-1000 nm and became constant at over 1000 nm. The concentrations of CPFX in rat AMs until 24 h after pulmonary administration of CPFX-liposomes with a particle size of 1000 nm were higher than the minimum inhibitory concentration of CPFX against various intracellular parasites. In a cytotoxic test, no release of lactate dehydrogenase (LDH) from rat lung tissues by pulmonary administration of CPFX-liposomes with a particle size of 1000 nm was observed. These findings indicate that efficient delivery of CPFX to AMs by CPFX-liposomes with a particle size of 1000 nm induces an excellent antibacterial effect without any cytotoxic effects on lung tissues. Therefore, CPFX-liposomes may be useful in the development of drug delivery systems for the treatment of respiratory infections caused by intracellular parasites, such as Mycobacterium tuberculosis, Chlamydia pneumoniae and Listeria monocytogenes.
机译:为了确认脂质体(CPFX-脂质体)中掺入的环丙沙星(CPFX)对于治疗呼吸道细胞内寄生虫感染的功效,在肺部给药CPFX-脂质体后,粒径对药物输送至大鼠肺泡巨噬细胞(AMs)的影响为调查。 CPFX脂质体是通过水合方法,以脂质摩尔比为7/2/1的氢化大豆磷脂酰胆碱(HSPC),胆固醇(CH)和磷酸二鲸蜡酯(DCP)制备的,然后调节至五种不同的粒径(100、200, 400、1000和2000 nm)。在药代动力学实验中,CPFX-脂质体经肺部给药后,CPFX向大鼠AM的递送效率随粒径的增加在100-1000 nm范围内增加,并在1000 nm以上恒定。肺部给药直径1000 nm的CPFX-脂质体后24小时内,大鼠AMs中CPFX的浓度高于CPFX对各种细胞内寄生虫的最小抑制浓度。在细胞毒性试验中,未观察到通过肺部施用1000 nm粒径的CPFX-脂质体从大鼠肺组织释放乳酸脱氢酶(LDH)。这些发现表明,粒径为1000 nm的CPFX脂质体有效地将CPFX递送至AMs诱导了优异的抗菌作用,而对肺组织没有任何细胞毒性作用。因此,CPFX-脂质体可用于开发药物递送系统以治疗由细胞内寄生虫引起的呼吸道感染,例如结核分枝杆菌,肺炎衣原体和单核细胞增生李斯特菌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号